Loading candles…
Aarti Drugs Ltd., incorporated in 1984, operates in the pharmaceuticals and specialty chemicals industries. The company manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and finished dosage formulations. It follows a vertically integrated business model and exports its APIs and specialty chemicals to over 100 countries across six continents. Aarti Drugs Ltd. includes Pinnacle Life Science Private Limited, its wholly-owned subsidiary focused on finished dosage formulations. The company holds leadership positions in therapeutic categories such as anti-protozoals and anti-inflammatory drugs. As part of the Aarti Group of Industries, valued at $1 billion, Aarti Drugs Ltd. has grown into a global leader for several high-volume molecules.
This page is a live market overview for AARTI DRUGS LTD. (AARTIDRUGS) on the NSE. As a listed security, AARTI DRUGS LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AARTIDRUGS before placing trades on tick2trade.
As of the latest feed, AARTIDRUGS last traded at ₹416.2 on NSE, up ₹5.35 (1.30%) from the previous close of ₹410.85. Today's session range is ₹409.85 – ₹418.15, against a 52-week band of ₹318.95 – ₹534.55. Traded volume today stands at 90.02K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for AARTIDRUGS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AARTIDRUGS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for AARTI DRUGS LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AARTIDRUGS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AARTIDRUGS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 15 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and Interim dividend for FY 2025-26, if any | 3 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 18 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 6 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.